Inflammatix

Inflammatix is a cutting-edge biotechnology firm that is disrupting healthcare by creating a point-of-care, precision medicine solution that, by reading a body’s immune response, can help determine whether a person has a bacterial or viral infection or a noninfectious condition. This is particularly relevant to detecting sepsis, a life-threatening organ dysfunction that is often misdiagnosed.

The Silicon Valley-based company was founded by Dr. Tim Sweeney, Jonathan Romanowsky, and Purvesh Khatri, and is led by an experienced executive team, and is backed by funds like OSF Ventures, Northpond Ventures, Khosla Ventures and others. The company’s main product, TriVerity, has already been recognized as a Breakthrough Device by the FDA, and is recognized by its speed — it has a 1-minute hands-on time and a turnaround time of 30 minutes.

Acute infection and sepsis are huge problems in healthcare, accounting for half of all hospital deaths and one-third of misdiagnosis-related harms in the United States. They also place an enormous burden on the hospital system, crowding emergency rooms and costing $53 billion to the Medicare program alone. Inflammatix’s solution, TriVerity, helps emergency physicians obtain better insights that inevitably lead to better outcomes, helping patients and medical institutions alike.